Background: A phase II study was conducted to evaluate the efficacy and safety of a combination regimen of a reduced dose intensity of docetaxel (Taxotere) plus capecitabine in pretreated patients with metastatic gastric cancer.
introduction
Although the incidence of gastric cancer is decreasing, the most part of patients are diagnosed with advanced disease because of early lymphogenic and hematogeneous spread. As a result, prognosis is poor with a 5-year survival of 10%-15% from diagnosis. So far advanced gastric cancer (AGC) remains a considerable challenge for oncologists with a median overall survival (OS) of only 6-9 months in patients receiving chemotherapy, and a platinum-based regimen is usually employed in these cases [1] . Even if many patients respond initially to chemotherapy, they ultimately relapse. In addition, a significant proportion of cases have primary refractory disease. To date, there are no currently established palliative treatment options for these patients. There is, therefore, a need for development of alternative, active drug combinations [2] . Docetaxel is an antimicrotubule agent that enhances polymerization of tubulin into stable microtubules and inhibits microtubule depolymerization [3] . As a single agent, the response rate (RR) of docetaxel is 17% in the second-line setting of patients with AGC [4] [5] [6] . Capecitabine is an oral fluoropyrimidine metabolized to 5-fluorouracil (5-FU) by a three-step process, the final step of which is mediated by thymidine phosphorylase (TP). Capecitabine has proven to be active as a single drug in advanced or recurrent gastric cancer [7] . Taxanes result in the up-regulation of TP in tumor tissue, which appears to further enhance tumor sensitivity to capecitabine [8] . A phase I study for patients with advanced solid tumors has shown that capecitabine and docetaxel can be combined safely and effectively, giving both agents at doses where they possess single-agent activity [9] . In light of the dosing schedule described in that trial, capecitabine (1250 mg/m 2 twice daily on days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and docetaxel (75 mg/m 2 on day 1), administered every 3 weeks, were tested in a large phase III study in pretreated metastatic breast cancer providing clear benefit in terms of RR, time to tumor progression (TTP) and OS over single-agent docetaxel [10] . This combination has symposium article /l), creatinine and total bilirubin <1.25 times the upper limit of normal, absence of other malignancies with the exception of basal skin/squamous cancer or in situ cervical carcinoma, no concurrent uncontrolled medical illness or pregnancy. Patients were Eastern Cooperative Oncology Group performance status of zero to two, had to have life expectancy of >3 months. Participants gave written informed consent before entering the study, which was approved by local Ethic Committee. Baseline investigations included classification of histology as well, full blood count, clotting screen, urea and electrolytes, creatinine clearance, liver function tests and tumor markers carcinoembryonic antigen and CA 19.9. An Electrocardiogram (ECG) was carried out along with baseline CT scan of thorax, abdomen and pelvis with bidimensional evaluation of measurable disease.
treatment plan
Oral capecitabine was administered at a dose of 1000 mg/m 2 twice daily on days 1-14 every 3 weeks. Docetaxel was administered at a dose of 60 mg/m 2 i.v. on day 1 every 3 weeks following premedication with dexamethasone 8 mg twice daily on days 0-2 for 3 days. Docetaxel was given 1 h before the first oral dose of capecitabine. Patients underwent follow-up CT scans for assessment of response after every three cycles of therapy. Evaluations were classified on the basis of the criteria defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines [16] . Patients were treated until best response or until there was evidence of disease progression, unacceptable toxicity, consent withdrawal or death. Complete blood cell counts with differential and serum biochemistry analyses were performed every week. Safety evaluation was determined using the National Cancer Institute Common Toxicity Criteria (version 3.0).
dose modification for adverse events
Capecitabine treatment interruption or dose reduction was not indicated in case of grade 1 toxicity. Treatment was interrupted in cases of grade 2 or higher events (with the exception of alopecia, nausea or vomiting and anemia) and was not resumed until the adverse effect resolved or improved to grade 1 or 0. Capecitabine dose reduction was not required at the first occurrence of a grade 2 event. Capecitabine dose was reduced by 20% for patients who experienced a second occurrence of a given grade 2 event or any grade 3 event. Capecitabine doses were reduced by 40% for patients who experienced a third occurrence of a given grade 2 event, a second occurrence of a given grade 3 event or any grade 4 event. Treatment was discontinued if, despite dose reduction, a given adverse event occurred for a fourth time at grade 2, a third time at grade 3 or a second time at grade 4.
If an adverse event did not improve to grade 1 or less after 3 weeks, the affected patient was withdrawn from the study. Docetaxel treatment was interrupted in cases of grade 2 or higher event and was not resumed until the adverse effect resolved or improved to grade 1 or 0. For patients who had developed grade 4 hematological toxicity, a 20% permanent dose reduction was required. Treatment was discontinued in cases of grade 3 or 4 neuropathy. Patients who developed hepatic abnormalities during therapy received a 20% dose reduction if there was an increase in aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase of between 2.5 and 5 · UNL. Elevations of any of these enzymes to >5 · UNL required docetaxel suspension for a maximum of 3 weeks; the patient was taken off the study if they did not recover within that time frame.
statistical considerations
The trial was designed as a two-stage study according to Gehan [17] , assuming a RR of 30%. With a power of 90%, this resulted in a sample size of seven patients for the first stage. The size of the second stage was determined by the observed number of responses and by the prespecified precision of 10%. There were three responders during the first stage of the study. Therefore, according to the study design, the sample size for the whole study was extended to at least 24 patients. Response duration was measured from the onset of response until disease progression. TTP was the interval from the starting date of therapy to the date of progression; survival was the interval from the starting date of therapy to the date of death. All analyses were made on an intention-to-treat (ITT) basis. Patients who did not finish three treatment cycles, whatever the reason, were considered treatment failures and listed as disease progressions. OS and TTP were calculated using the Kaplan-Meier method since the start of chemotherapy [18] . The 95% confidence interval (95% CI) was also calculated. Table 1 . Of these, all patients were assessable for safety and 25 for tumor response. The median age of patients was 63 years (range 26-70), and the majority of patients were in good condition as documented by a PS of zero or one in 75%. In all, 13 patients (47%) had multiple metastases involving two or more organ systems. The most common metastatic site was the abdominal lymph nodes (64%), and the most common metastatic organ was the liver (46%). Ten of the patients (36%) had undergone radical subtotal gastrectomy and two (7%) received prior radiation therapy.
efficacy
Patients completed a median of four cycles (range 1-6) of treatment. Twenty-five out of 28 patients (89%) were assessable for response. Three patients were not assessable but were included in the ITT analysis and kept in the denominator of the RR. One patient refused to continue treatment after two cycles of therapy because of personal reasons. Two patients did not complete two cycles of chemotherapy as they died before the first tumor assessment was carried out. These cases were categorized as failure in evaluation of response. Table 2 shows the results. Eight patients showed a partial response, with an overall RR of 29% (95% CI 11% to 46%). Ten patients showed safety Toxicities are summarized in Table 3 . Treatment was generally well tolerated in the majority of patients. A total of 104 treatment cycles (median 3, range 1-6 cycles) were administered. The most common clinical adverse events (all ITT, intention-to-treat; PR, partial response; SD, stable disease; PD, progression disease; CI, confidence interval; TTP, time to tumor progression. symposium article Annals of Oncology grades) were neutropenia (78%), HFS (53%), fatigue and alopecia (50%) and diarrhea (43%). However, with the exception of grade 3-4 neutropenia, which was seen in 36% of patients, other severe adverse events were rare. Neutropenic fever was reported in only two patients (7%). There were no treatment-related deaths. Treatment delays or dose reductions were necessary in 18 out of 104 cycles. Doses were reduced in 16 cycles (15%) as a result of severe neutropenia and diarrhea. In addition, two patients (7%) had dose reductions for HFS and onycholysis. Treatment was discontinued in one patient because of persistent grade 3 HFS. Treatment delays were observed in six cycles (6%). Although dose reductions were necessary at times, patients received most of the anticipated doses (median 80%-100%) of docetaxel and capecitabine for each of the planned cycles of chemotherapy.
discussion
This monoinstitutional phase II study evaluated a reduced dose intensity of docetaxel plus capecitabine as second-line therapy in patients with metastatic gastric cancer. The RR of 29% to this combination seems encouraging (95% CI 11% to 46%) with SD in a further 36% of patients. Median TTP is 4 months, and median OS is 6 months, indicating there is a role for second-line treatment in this setting of patients. On the other hand, the addition of capecitabine to docetaxel has also demonstrated to produce significant improvements in RR, TTP and OS in metastatic breast cancer [10] . In that phase III trial, capecitabine was administered at the dose of 1250 mg/m 2 twice daily for 14 days and docetaxel at the dose of 75 mg/m 2 on day 1, every 3 weeks. However, many patients (65%) had dose reductions for adverse events, and capecitabine and docetaxel were simultaneously reduced to 950 mg/m 2 and 55 mg/m 2 , respectively. A detailed safety and efficacy analysis of that study has reported that there were fewer cycles (17%) with grade 3-4 adverse events than with the full doses (34%). Moreover, the Kaplan-Meier curves for TTP and OS in patients with and without capecitabine/docetaxel dose reductions (cycle two onwards) were similar, indicating that drug's dose reduction did not compromise efficacy in terms of these end points [19] .
Previous clinical trials with this drug combination provide conflicting results in chemotherapy-naive patients with AGC [11] [12] [13] [14] [15] . Published tumor RRs ranged from 40% to 60% and OSs from 9.4 to 12 months in four out of five studies [11] [12] [13] [14] . Only an Italian study reported an unsatisfactory clinical response number (21%) and an OS of 7.7 months [15] . However, the low dose intensity of capecitabine (625 mg/m 2 per os on days 5-18) repeated every 4 weeks seems to justify these disappointing results.
Treatment was well tolerated in our trial with the predominant grade 3-4 toxic effects being neutropenia in 36% of patients, but only two of them (7%) developed febrile neutropenia. Non-hematological serious adverse events occurred in relatively few patients. The most frequently grade 3-4 reported event was diarrhea (11%). This gastrointestinal side-effect was manageable with transient capecitabine interruptions or dose modifications in the majority of cases. The above-mentioned studies evaluating docetaxel/capecitabine combination in patients with AGC reported sometimes remarkable toxic effects, dose reductions and treatment delays. While HFS and onycholysis appeared dose-limiting toxic effects in the study of Park et al. [12] , there was one treatment-related death and a high percentage (77%) of patients developing grade 3-4 neutropenia in the study of Giordano et al. [13] . In addition, grade 3 stomatitis occurred in 25.5% of cases leading to dose reductions in 11 patients (20.0%), and nail changes appeared frequent (65.4%) and sometimes problematic in patients with prolonged treatment in the study of Chun et al. [11] .
Based on these data, combination therapy with docetaxel and capecitabine at this tested dose schedule appears relatively well tolerated and feasible as an outpatient regimen in our experience. Consisting with the O'Shaughnessy's proposal, a reduced dose intensity of docetaxel and capecitabine does not seem to limit the effectiveness of the treatment in second-line chemotherapy in AGC. This approach warrants further investigation as a promising chemotherapy option for chemonaive patients with AGC. 
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